Alto Neuroscience Statistics
Total Valuation
ANRO has a market cap or net worth of $638.59 million. The enterprise value is $487.98 million.
Important Dates
The last earnings date was Monday, March 16, 2026, before market open.
| Earnings Date | Mar 16, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ANRO has 31.95 million shares outstanding. The number of shares has increased by 17.28% in one year.
| Current Share Class | 31.95M |
| Shares Outstanding | 31.95M |
| Shares Change (YoY) | +17.28% |
| Shares Change (QoQ) | +26.12% |
| Owned by Insiders (%) | 4.29% |
| Owned by Institutions (%) | 36.88% |
| Float | 19.15M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.23 |
| P/TBV Ratio | 4.24 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 15.69, with a Debt / Equity ratio of 0.16.
| Current Ratio | 15.69 |
| Quick Ratio | 15.58 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -26.88 |
Financial Efficiency
Return on equity (ROE) is -41.80% and return on invested capital (ROIC) is -24.15%.
| Return on Equity (ROE) | -41.80% |
| Return on Assets (ROA) | -22.90% |
| Return on Invested Capital (ROIC) | -24.15% |
| Return on Capital Employed (ROCE) | -38.28% |
| Weighted Average Cost of Capital (WACC) | 18.11% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$832,079 |
| Employee Count | 76 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +653.77% in the last 52 weeks. The beta is 2.59, so ANRO's price volatility has been higher than the market average.
| Beta (5Y) | 2.59 |
| 52-Week Price Change | +653.77% |
| 50-Day Moving Average | 18.59 |
| 200-Day Moving Average | 10.41 |
| Relative Strength Index (RSI) | 47.90 |
| Average Volume (20 Days) | 277,299 |
Short Selling Information
The latest short interest is 2.04 million, so 6.40% of the outstanding shares have been sold short.
| Short Interest | 2.04M |
| Short Previous Month | 2.14M |
| Short % of Shares Out | 6.40% |
| Short % of Float | 10.67% |
| Short Ratio (days to cover) | 9.35 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -66.36M |
| Pretax Income | -63.24M |
| Net Income | -63.24M |
| EBITDA | -65.70M |
| EBIT | -66.36M |
| Earnings Per Share (EPS) | -$2.19 |
Full Income Statement Balance Sheet
The company has $176.48 million in cash and $23.96 million in debt, with a net cash position of $152.53 million or $4.77 per share.
| Cash & Cash Equivalents | 176.48M |
| Total Debt | 23.96M |
| Net Cash | 152.53M |
| Net Cash Per Share | $4.77 |
| Equity (Book Value) | 151.14M |
| Book Value Per Share | 4.73 |
| Working Capital | 166.39M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$51.77 million and capital expenditures -$24,000, giving a free cash flow of -$51.79 million.
| Operating Cash Flow | -51.77M |
| Capital Expenditures | -24,000 |
| Depreciation & Amortization | 661,000 |
| Net Borrowing | 10.23M |
| Free Cash Flow | -51.79M |
| FCF Per Share | -$1.62 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ANRO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.28% |
| Shareholder Yield | -17.28% |
| Earnings Yield | -9.87% |
| FCF Yield | -8.09% |
Analyst Forecast
The average price target for ANRO is $27.63, which is 38.22% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $27.63 |
| Price Target Difference | 38.22% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |